Journal
VACCINE
Volume 39, Issue 12, Pages 1670-1674Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.02.031
Keywords
Vaccine; Escherichia coli; ExPEC; ICU; Bloodstream infections
Categories
Funding
- Innovative Medicine Initiative (IMI)
- European Union
- EFPIA companies [115 620]
Ask authors/readers for more resources
This study investigated E. coli BSI in ICU patients in the Netherlands and identified common O-serogroups. The research suggests that a vaccine currently in development may help prevent E. coli BSI.
Objectives: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. Methods: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. Results: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates sero-grouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). Conclusions: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients. (C) 2021 The Author(s). Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available